NCT03585101撤回4 期
A Single-arm Evaluation of the Effect of Elbasvir/Grazoprevir on Cardiometabolic Parameters in Patients With Hepatitis C Infection and Underlying Metabolic Disease
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Change in reactive hyperemia index (RHI) by peripheral arterial tonometry (PAT)
研究概览
简要总结
This study will assess the effect of treatment for hepatitis C virus (HCV) on cardiovascular disease risk. The study will enroll men and women who are infected with HCV and have underlying metabolic disease. All participants will receive a 12-week course of an HCV treatment (elbasvir/grazoprevir). Cardiovascular disease risk will be evaluated at baseline, week 4 on treatment, 12 weeks post-treatment, and 52 weeks post-treatment through noninvasive measurements of endothelial function, insulin resistance, liver fibrosis and steatosis, and circulating blood biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥ 18 years of age.
- •Presence of HCV infection for at least 12 weeks
- •Serum or plasma HCV RNA > lower limit of quantification or detection at any time before or at the time of screening, and the absence of intervening HCV treatment
- •Absence of HIV infection
- •HCV treatment-naïve OR HCV treatment-experienced with PEG-IFN/RBV only (no prior HCV DAA exposure)
- •Genotype 1 or 4 HCV infection. If HCV genotype 1a infection is present, absence of genotype 1a NS5A resistance associated substitutions (RASs) at amino acid positions 28, 30, 31, and 93 must be documented at screening
- •Evidence of metabolic disease defined as:
- •Insulin resistance or impaired glucose tolerance by one of the following:
- •HOMA-IR ≥2.5 at screening
- •Hemoglobin A1c 5.7-6.4% at screening
- •Diabetes mellitus with hemoglobin A1c <7% at screening and never on more than one oral hypoglycemic agent, as well as never requiring insulin
- •Metabolic Syndrome, defined as at least 3 of the following:
- •Waist circumference ≥102 cm for men and ≥ 88 cm for women
- •Serum triglyceride level ≥150 mg/dL or on a triglyceride lowering agent
- •Serum high-density lipoprotein (HDL) cholesterol <40 mg/dL in men and <50 mg/dL in women or drug treatment for low HDL cholesterol
- •Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure
- •Fasting blood glucose ≥100 mg/dL
- •Ability and willingness of subject to provide written informed consent
排除标准
- •History of decompensated liver disease (Child Pugh Class B or C)
- •Albumin below 3 g/dL
- •Platelet count below 75,000
- •HBsAg positivity.
- •Pregnancy or breastfeeding
- •Inability to conform to the following drug interruptions for PAT testing, whether due to safety (determined by the investigator) or willingness: No caffeine or recreational or prescription stimulant use for 24 hours prior; no nicotine for 4 hours prior; no vigorous exercise for 12 hours prior; stopping of beta blockers, short-acting calcium channel blockers (CCBs), nitrates, angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin-receptor blockers (ARBs), and renin-inhibitors for 24 hours prior; and stopping of long acting CCBs 48 hours prior to testing.
- •Use of anticoagulant or antiplatelet agents (other than aspirin ≤ 325 mg orally daily) within 1 week prior to study entry or anticipated need for these agents for >7 days during the study follow-up period.
- •Use of contraindicated concomitant medications, including OATP1B1/3 inhibitors and strong CYP3A inducers
- •Serious illness including acute liver-related disease and malignancy requiring systemic treatment or hospitalization within 12 weeks prior to study entry.
- •History of major organ transplantation with an existing functional graft and on immunosuppressive therapy.
- •History of known vascular disorder or autoimmune processes including Crohn's disease, ulcerative colitis, severe psoriasis, rheumatoid arthritis, and cryoglobulinemia that may affect vascular studies.
- •Decompensated congestive heart failure or acute cardiovascular event (such as stroke, myocardial infarction, arrhythmia, acute peripheral arterial insufficiency) within 6 months prior to study entry
- •Use of immune-based therapies or systemic corticosteroids which may affect vascular studies or inflammatory/endothelial biomarkers within 12 weeks prior to study entry
- •Advanced renal insufficiency as defined by glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 or treatment by dialysis
- •Anticipated inability to comply with research study visits as determined by the investigator
- •Poor venous access not allowing screening laboratory collection
- •Having any condition that the investigator considers a contraindication to study participation
研究组 & 干预措施
All participants
Experimental
Intervention: Elbasvir/grazoprevir
干预措施: Elbasvir/grazoprevir (Drug)
结局指标
主要结局
Change in reactive hyperemia index (RHI) by peripheral arterial tonometry (PAT)
时间窗: Baseline to 12 weeks after end of EBR/GZR treatment.
次要结局
- Change in hemoglobin A1c(Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment)
- Change in total and LDL cholesterol levels(Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment)
- Cross-sectional steatosis score in dB/m by CAP for correlation with RHI and soluble biomarkers at the same time points(Baseline and 12 and 52 weeks after end of treatment)
- Change in hepatic steatosis score by CAP(Baseline to 52 weeks after end of treatment)
- Change in insulin resistance by HOMA-IR(Baseline to 52 weeks after end of treatment)
- Change in reactive hyperemia index (RHI) by PAT(Baseline to 52 weeks after end of treatment)
- Change in levels of each soluble biomarker (sCD163, sCD14, sICAM-1, PAI-1, sE-selectin, oxidized LDL, Lp-PLA2, and lipoprotein particle quantification)(Baseline to week 4, baseline to 12 weeks after end of treatment, and baseline to 52 weeks after end of treatment)
- Cross-sectional levels of each soluble biomarker (sCD163, sCD14, sICAM-1, PAI-1, sE-selectin, oxidized LDL, Lp-PLA2, and lipoprotein particle quantification) at each time point for correlation with RHI(Baseline, week 4, post-treatment weeks 12 and 52)
- Cross-sectional fibrosis score in kPa by transient elastography (TE) for correlation with RHI and soluble biomarkers(Baseline and 12 and 52 weeks after end of treatment)
- Change in fibrosis score by transient elastography(Baseline to 52 weeks after end of treatment)
研究者
Kara Chew
Assistant Clinical Professor of Medicine
University of California, Los Angeles
研究点 (1)
Loading locations...
相似试验
终止
4 期
Impact of Hepatitis C Therapy and Bone HealthHuman Immunodeficiency VirusHepatitis CNCT03221582Dallas VA Medical Center6
已完成
3 期
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)Hepatitis C Virus (HCV)NCT04903626AbbVie286
已完成
1 期
Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole TabletDeglutition DisordersHepatitis CNCT03817619Radboud University Medical Center11
已完成
3 期
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected PatientsChronic HCV HepatitisNCT03496233Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo75
已完成
2 期
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionHepatitis CLiver DiseaseNCT02094443Debiopharm International SA52